Pheophorbide a is a specific probe for ABCG2 function and inhibition

被引:301
作者
Robey, RW
Steadman, K
Polgar, O
Morisaki, K
Blayney, M
Mistry, P
Bates, SE
机构
[1] NCI, Canc Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] Xenova Res, Slough, Berks, England
关键词
D O I
10.1158/0008-5472.CAN-03-3298
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pheophorbide a (PhA), a chlorophyll catabolite, was shown to be an ABCG2 substrate based on Abcg2(-/-) knockout mouse studies (J. W. Jonker et al., Proc. Natl. Acad. Sci. USA, 99: 15649-15654, 2002). We developed a functional assay for ABCG2 using PhA and the ABCG2 inhibitor fumitremorgin C. In selected cell lines expressing high levels of P-glycoprotein, multidrug resistance-associated protein 1, or ABCG2, PhA transport was observed only in cells expressing ABCG2. Fumitremorgin C-inhibitable PhA transport was found to correlate with cell surface ABCG2 expression as measured by the anti-ABCG2 antibody 5D3. We found that 100 mum of the cyclin-dependent kinase inhibitor UCN-01 or 1 mum of the P-glycoprotein inhibitor tariquidar inhibited ABCG2-mediated PhA transport. In 4-day cytotoxicity assays, ABCG2-mediated resistance to SN-38 and topotecan was abrogated in ABCG2-transfected HEK-293 cells treated with 1 lam tariquidar, and ABCG2-transfected cells were 6-7-fold resistant to UCN-01. PhA is an ABCG2-specific substrate with potential value in measuring ABCG2 function and expression in clinical samples.
引用
收藏
页码:1242 / 1246
页数:5
相关论文
共 22 条
[11]   Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918 [J].
Kruijtzer, CMF ;
Beijnen, JH ;
Rosing, H ;
Huinink, WWT ;
Schot, M ;
Jewell, RC ;
Paul, EM ;
Schellens, JHM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (13) :2943-2950
[12]   Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia [J].
Legrand, O ;
Simonin, G ;
Beauchamp-Nicoud, A ;
Zittoun, R ;
Marie, JP .
BLOOD, 1999, 94 (03) :1046-1056
[13]  
Leonard Gregory D, 2002, Curr Opin Investig Drugs, V3, P1652
[14]   Flow cytometric analysis of breast cancer resistance protein expression and function [J].
Minderman, H ;
Suvannasankha, A ;
O'Loughlin, KL ;
Scheffer, GL ;
Scheper, RJ ;
Robey, RW ;
Baer, MR .
CYTOMETRY, 2002, 48 (02) :59-65
[15]  
Mistry P, 2001, CANCER RES, V61, P749
[16]  
Miyake K, 1999, CANCER RES, V59, P8
[17]   Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells [J].
Nakatomi, K ;
Yoshikawa, M ;
Oka, M ;
Ikegami, Y ;
Hayasaka, S ;
Sano, K ;
Shiozawa, K ;
Kawabata, S ;
Soda, H ;
Ishikawa, T ;
Tanabe, S ;
Kohno, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 288 (04) :827-832
[18]   Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter -: Modulation of substrate specificity by a point mutation [J].
Özvegy, C ;
Váradi, A ;
Sarkadi, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (50) :47980-47990
[19]  
Robey RW, 2001, CLIN CANCER RES, V7, P145
[20]   A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2) [J].
Robey, RW ;
Honjo, Y ;
van de Laar, A ;
Miyake, K ;
Regis, JT ;
Litman, T ;
Bates, SE .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2001, 1512 (02) :171-182